2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139769
    Antibacterial agent 52 1426572-60-2 98%
    Antibacterial agent 52 (example 18) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 52
  • HY-139770
    Antibacterial agent 53 1426572-61-3 98%
    Antibacterial agent 53 (example 19) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 53
  • HY-139771
    Antibacterial agent 54 1426572-62-4 98%
    Antibacterial agent 54 (example 20) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 54
  • HY-139772
    Antibacterial agent 55 1426572-63-5 98%
    Antibacterial agent 55 (example 21) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 55
  • HY-139773
    Antibacterial agent 56 1426572-64-6 98%
    Antibacterial agent 56 (example 22) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 56
  • HY-139774
    Antibacterial agent 57 1426572-67-9 98%
    Antibacterial agent 57 (example 25) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 57
  • HY-139776
    Antibacterial agent 59 1426572-66-8 98%
    Antibacterial agent 59 (example 24) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 59
  • HY-139778
    Antibacterial agent 61 1426572-69-1 98%
    Antibacterial agent 61 (example 27) is a antibacterial agent (extracted from patent WO2013030735A1).
    Antibacterial agent 61
  • HY-139833
    Anti-inflammatory agent 6 98%
    Anti-inflammatory agent 6 blocks the phosphorylation of I kappa b kinase α/β (IKKα/β), IκBα, and nuclear factor kB p65 (NF-κB p65) which is a key controller of inflammation, thereby showing anti-inflammatory potential.
    Anti-inflammatory agent 6
  • HY-139844
    Anti-inflammatory agent 7 2759194-24-4 98%
    Anti-inflammatory agent 7 inhibits proinflammatory cytokines by blocking the NF-κB/MAPK signaling pathway in LPS-treated RAW 264.7 cells as well as mice.
    Anti-inflammatory agent 7
  • HY-139874
    CXCR2 antagonist 3 2647464-92-2 98%
    CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3+ T lymphocytes into the Pan02 tumor tissues.
    CXCR2 antagonist 3
  • HY-139878
    MLKL-IN-1 2837019-30-2 98%
    MLKL-IN-1 is a covalent MLKL inhibitor with a KD of 50 μM.
    MLKL-IN-1
  • HY-139906
    CXCL12 ligand 1 2045891-59-4 98%
    CXCL12 ligand 1 is the first ligand of the sY12-binding pocket on chemokine CXCL12.
    CXCL12 ligand 1
  • HY-139907
    DG013A 2007955-07-7 98%
    DG013A is a phosphinic acid tripeptide mimetic inhibitor. DG013A displays significantly weak affinity for both ERAP1 (IC50=33 nM) and ERAP2 (IC50=11 nM). DG013A can be used for the research of autoimmune disease and cancer.
    DG013A
  • HY-139938
    (±)11(12)-EET methyl ester 90693-45-1 98%
    (±)11(12)-EET methyl ester (11,12-EET-methyl ester) is a methylated derivative of 11,12-epoxyeicosatrienoic acid (11,12-EET) (HY-130494). (±)11(12)-EET methyl ester cannot induce β-arrestin recruitment of the G protein-coupled receptor GPR132. (±)11(12)-EET methyl ester fails to enhance the expression of hematopoietic stem and progenitor cell (HSPC) markers. (±)11(12)-EET methyl ester can be used as a negative control molecule to study the structure-function relationship of 11,12-EET, facilitating the analysis of the role of the oxygenated fatty acid-GPR132 signaling axis in hematopoiesis.
    (±)11(12)-EET methyl ester
  • HY-141420
    PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium 799268-62-5 98%
    PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium (compound 850176) is a vaccine adjuvant that enhances the immune function of vaccines.
    PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium
  • HY-141439
    TBE 31 936475-62-6 98%
    TBE 31 is a potent and orally active NQO1 inducer with an Dm value of 1.1 nM. TBE 31 also is a potent Nrf2 activator. TBE 31 reacts with cysteines of Keap1, impairing its ability to target nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) for degradation. TBE 31 shows cytoprotective effects.
    TBE 31
  • HY-141535
    IL-17 modulator 1 2446803-85-4 98%
    IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis.
    IL-17 modulator 1
  • HY-141547
    Nav1.7-IN-8 1432913-44-4 98%
    Nav1.7-IN-8 is a potent blockage of NaV1.7 with high selectivity for the inhibition of NaV1.7 over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits CYP2C9 and CYP3A4 with an IC50 of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain.
    Nav1.7-IN-8
  • HY-14157A
    ADL-5747 hydrochloride 1187653-56-0 98%
    ADL-5747 hydrochloride is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 hydrochloride activates these receptors, thereby playing a role in pain management pathways. ADL-5747 hydrochloride can be used for research into pain management mechanisms.
    ADL-5747 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity